Trazodone Side Effects: Potentially Permanent Adverse Events

What Makes a Trazodone Side Effect "Potentially Permanent"?

Most adverse drug reactions resolve once the offending agent is stopped. A subset do not. For trazodone, "potentially permanent" means the pathology either causes irreversible structural damage (priapism-induced fibrosis, cardiac scarring) or persists as a self-sustaining neurobiological state (PSSD, tardive movement disorders) that continues after full elimination of the drug.

The FDA's current prescribing information for trazodone carries explicit warnings for priapism and cardiac arrhythmia, both of which carry a documented risk of lasting harm. [1] Post-market surveillance through the FDA Adverse Event Reporting System (FAERS) has expanded that picture to include sexual dysfunction persisting after discontinuation, movement abnormalities, and hyponatremia-related neurological sequelae.

Why Duration and Dose Matter

Longer exposure and higher doses increase the probability of receptor-level adaptations that do not fully reverse. A 2021 pharmacovigilance analysis of FAERS data found that reports of persistent sexual dysfunction after serotonergic antidepressants, including trazodone, disproportionately involved patients who had taken the drug for more than six months. [2]

Short-term, low-dose use for insomnia (25 to 100 mg nightly) appears to carry lower absolute risk for most of the permanent adverse events described below, but published case reports document priapism even at the 50 mg dose. [3]

Individual Vulnerability Factors

CYP3A4 poor metabolizers accumulate trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) at higher plasma concentrations, amplifying receptor-mediated toxicity. Patients also taking CYP3A4 inhibitors such as ketoconazole or ritonavir may face two- to three-fold increases in trazodone exposure. [1]

Priapism: The Most Documented Permanent Risk

Priapism, a painful erection lasting more than four hours without sexual arousal, is the single most widely cited potentially permanent complication of trazodone. The FDA label states the incidence is approximately 1 in 6,000 male patients. [1] That figure likely underestimates real-world occurrence given underreporting of a stigmatized condition.

Mechanism

Trazodone's alpha-1 adrenergic antagonism disrupts the detumescence reflex. Normally, norepinephrine-mediated alpha-1 receptor activation constricts the helicine arteries and closes the corporal sinusoids after an erection. Blockade of this pathway allows uncontrolled arterial inflow with no outflow, producing ischemic priapism. Tissue hypoxia begins within two to four hours; irreversible smooth-muscle necrosis and subsequent fibrosis can occur by six hours. [4]

Outcomes and Permanence

Ischemic priapism extending beyond six hours carries a reported erectile dysfunction (ED) rate of roughly 50%, rising to near-total ED after 24 hours without intervention, based on a 2014 review of ischemic priapism outcomes published in the Journal of Sexual Medicine. [4] Surgical shunting or penile prosthesis implantation may be required.

Several case reports document men who developed permanent ED after a single episode of trazodone-induced priapism at doses as low as 50 mg. [3] The permanence here is structural: collagen replaces erectile smooth muscle and the injury does not heal regardless of trazodone discontinuation.

Who Is at Higher Risk

Men with sickle cell disease, other hemoglobinopathies, or baseline coagulopathies face amplified risk. Co-administration of phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or other alpha-blockers additively impairs detumescence. The FDA label recommends that any male patient experiencing an erection lasting more than four hours discontinue trazodone and seek emergency care immediately. [1]

Post-SSRI / Serotonergic Sexual Dysfunction (PSSD)

PSSD describes a cluster of sexual symptoms, including genital numbness, anorgasmia, reduced libido, and erectile or lubrication dysfunction, that persist for months to years after stopping a serotonergic drug. Trazodone, though classified as a SARI rather than an SSRI, acts on serotonin transporters and 5-HT receptors and has appeared in PSSD case series. [2]

Regulatory Recognition

The European Medicines Agency reviewed PSSD evidence in 2019 and mandated label updates across all SSRIs and SNRIs sold in the EU to include a warning about persistent sexual dysfunction. [5] The EMA's safety committee concluded: "There is sufficient evidence of a causal relationship between SSRIs/SNRIs and the occurrence of long-lasting sexual dysfunction after treatment discontinuation." [5] Trazodone was not the primary focus of that review but shares mechanistic overlap through 5-HT2A and 5-HT2C antagonism.

Symptoms That May Not Resolve

Clinicians can organize PSSD symptoms into three domains for assessment and monitoring:

Sensory domain. Genital anesthesia or paresthesia, sometimes described by patients as "numbness" or a loss of orgasmic sensation. Case series indicate this may be the symptom least likely to resolve spontaneously. [2]

Arousal domain. Reduced or absent libido, failure to achieve erection or lubrication despite adequate stimulation, delayed ejaculation. These symptoms overlap considerably with underlying depression but persist in patients who are otherwise in full depressive remission.

Cognitive-emotional domain. Emotional blunting, described as a "flatness" of affect that extends beyond sexual experience. This symptom is also reported after discontinuation of trazodone used purely for insomnia, suggesting it is not solely a residual feature of treated depression. [6]

No FDA-approved treatment for PSSD exists as of mid-2025. Small open-label reports have explored bupropion, buspirone, and low-dose testosterone, but no randomized controlled trial data are available.

Cardiac Conduction Abnormalities

Trazodone prolongs the cardiac QT interval through blockade of the hERG potassium channel (IKr). QT prolongation raises the risk of torsades de pointes (TdP), a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. Death or hypoxic brain injury from a TdP episode represents a permanent outcome.

Evidence from FAERS and Case Reports

A 2020 pharmacovigilance study querying FAERS for trazodone and cardiac events identified 412 reports of QT prolongation or related arrhythmia over a 10-year window, with 38 fatalities. [7] TdP appears more frequently in patients with pre-existing QTc >450 ms, hypokalemia, or concurrent use of other QT-prolonging agents (macrolide antibiotics, antipsychotics, methadone).

The Arizona CERT drug interaction program classifies trazodone as a "known risk" QT-prolonging drug. [8] Patients who survive a TdP episode may develop post-arrest hypoxic encephalopathy or myocardial injury, both of which can be permanent.

Practical Monitoring

Baseline ECG is advisable before starting trazodone in patients with cardiac disease, electrolyte abnormalities, or polypharmacy. Repeat ECG is warranted if the QTc at baseline is >450 ms. A corrected QTc exceeding 500 ms should prompt discontinuation and cardiology referral. [8]

Serotonin Syndrome and Its Sequelae

Serotonin syndrome is an acute toxidrome produced by excessive serotonergic activity. Trazodone, combined with MAOIs, other serotonergic antidepressants, tramadol, linezolid, or certain migraine triptans, can precipitate severe serotonin syndrome. [1]

When Acute Becomes Permanent

Most serotonin syndrome cases resolve within 24 hours of stopping the offending agents and administering cyproheptadine. Severe cases with prolonged hyperthermia (core temperature >41°C) can cause:

• Rhabdomyolysis leading to acute kidney injury, which in 10 to 25% of severe cases progresses to chronic kidney disease [9]
• Hypoxic brain injury from seizures or cardiac arrest
• Peripheral neuropathy from ischemia during prolonged muscle rigidity

A 2016 systematic review in the BMJ found that mortality from serotonin syndrome in hospitalized patients was 2 to 12%, with survivors of severe cases having measurable neurological deficits at six-month follow-up in approximately 15% of documented reports. [9]

Drug Combinations to Avoid

The FDA label for trazodone contraindicates concurrent use with MAOIs and requires a 14-day washout after stopping an MAOI before starting trazodone. [1] Linezolid and intravenous methylene blue, both MAO inhibitors, are also listed as contraindicated. Co-prescription with tramadol, fentanyl, or lithium requires heightened vigilance.

Movement Disorders: Rare but Potentially Irreversible

Tardive dyskinesia (TD) and other movement abnormalities are most commonly associated with dopamine-blocking antipsychotics, but serotonergic agents, including trazodone, have appeared in case reports of TD-like syndromes.

mCPP and Dopamine Interactions

Trazodone's metabolite mCPP is a serotonin 5-HT2C agonist and has indirect dopaminergic activity. A 2018 case series published in the Journal of Clinical Psychopharmacology described three patients who developed oro-facial dyskinesias after 12 to 36 months of trazodone therapy that persisted six to 12 months after drug withdrawal. [10] Whether these represent true tardive dyskinesia or a separate serotonin-mediated movement disorder remains unresolved.

Tardive dyskinesia, once established, is permanent in roughly 50% of affected patients even after drug discontinuation, based on FDA review data supporting valbenazine approval for TD. [11]

Hyponatremia and Neurological Injury

Trazodone, like other serotonergic agents, can cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), resulting in hyponatremia. Severe hyponatremia (serum sodium <125 mEq/L) causes cerebral edema, and over-rapid correction causes osmotic demyelination syndrome (ODS).

ODS: A Preventable Permanent Injury

ODS destroys myelin in the pontine and extrapontine white matter. Survivors can be left with spastic quadriplegia, dysphagia, locked-in syndrome, or cognitive impairment. The correction rate for severe hyponatremia must not exceed 8 to 10 mEq/L per 24 hours, per Endocrine Society clinical guidelines. [12]

Elderly patients, women, and patients with low baseline serum sodium are at highest risk for trazodone-related SIADH. A retrospective cohort study of 75,000 antidepressant users found that serotonergic agents increased SIADH odds by 3.4-fold in adults over age 65 compared with noradrenergic agents. [13]

Ocular Effects: Emerging Concern

Angle-closure glaucoma is an acute, potentially vision-threatening event linked to serotonergic and anticholinergic agents. Trazodone's alpha-adrenergic blockade may precipitate angle closure in patients with narrow anterior chamber angles by relaxing the ciliary muscle.

Acute angle-closure glaucoma, if not treated within hours, causes permanent optic nerve damage and irreversible vision loss. [14] Any patient reporting sudden eye pain, blurred vision, or halos around lights while taking trazodone warrants same-day ophthalmology evaluation.

Monitoring Protocol for Long-Term Trazodone Use

Patients remaining on trazodone beyond 90 days should undergo systematic monitoring for the adverse effects described above.

Recommended Assessments

Baseline (before starting). ECG (for QTc), serum sodium, renal function panel, blood pressure (supine and standing for orthostatic hypotension risk), sexual function baseline questionnaire (Arizona Sexual Experience Scale or similar), and ophthalmology referral if narrow-angle glaucoma risk factors are present.

At 4 to 8 weeks. Repeat serum sodium in patients >65 years or on diuretics. Review sexual function symptoms. Ask men directly about prolonged erections.

At 3 months and every 6 months thereafter. Repeat ECG if baseline QTc was >430 ms. Reassess sexual function. Screen for involuntary movements using the Abnormal Involuntary Movement Scale (AIMS) if the patient reports facial or limb movements.

At any point. Immediate evaluation for priapism (erection >4 hours), acute cardiac symptoms, signs of serotonin toxicity (agitation, clonus, hyperthermia, diaphoresis), or sudden visual changes.

Discontinuation: Is Stopping Trazodone Itself a Risk?

Abrupt discontinuation of trazodone after prolonged use can produce a discontinuation syndrome characterized by dizziness, nausea, anxiety, and sleep rebound. While not permanent, the discomfort leads some patients to restart the drug and delay detection of emerging adverse effects.

The recommended taper is a 10 to 25% dose reduction every one to two weeks, with the final steps taking the longest. No formal RCT has defined an optimal taper schedule specifically for trazodone; the guidance is extrapolated from general antidepressant discontinuation literature and expert consensus. [15]